$4.66
0.00%
Nasdaq, Fri, Oct 02 2026.
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Target price 2026 - Analyst rating & recommendation

CureVac N.V. Classifications & Recommendation

Buy
55%
Hold
45%

CureVac N.V. Price Target

Target Price $5.57
Price $4.66
Potential
Number of Estimates 7
7 Analysts have issued a price target CureVac N.V. 2027 . The average CureVac N.V. target price is $5.57. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 6 Analysts recommend CureVac N.V. to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CureVac N.V. stock has an average upside potential 2027 of . Most analysts recommend the CureVac N.V. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 602.32 81.81
895.57% 86.42%
EBITDA Margin 36.83% -156.08%
107.97% 523.81%
Net Margin 30.30% -144.72%
106.26% 577.55%

7 Analysts have issued a sales forecast CureVac N.V. 2025 . The average CureVac N.V. sales estimate is

$81.8m
unlock
. This is
2.75% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$124m 55.84%
unlock
, the lowest is
$37.7m 52.71%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $602m 895.57%
2025
$81.8m 86.42%
unlock
2026
$101m 23.71%
unlock
2027
$171m 68.51%
unlock
2028
$226m 32.68%
unlock
2029
$286m 26.30%
unlock
2030
$331m 15.74%
unlock

5 Analysts have issued an CureVac N.V. EBITDA forecast 2025. The average CureVac N.V. EBITDA estimate is

$-128m
unlock
. This is
167.68% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-63.8m 133.83%
unlock
, the lowest is
$-166m 187.92%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $222m 179.31%
2025
$-128m 157.56%
unlock
2026
$-128m 0.04%
unlock
2027
$-36.9m 71.14%
unlock

EBITDA Margin

2024 36.83% 107.97%
2025
-156.08% 523.81%
unlock
2026
-126.21% 19.14%
unlock
2027
-21.61% 82.88%
unlock

7 CureVac N.V. Analysts have issued a net profit forecast 2025. The average CureVac N.V. net profit estimate is

$-118m
unlock
. This is
181.65% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-31.9m 122.02%
unlock
, the lowest is
$-176m 221.62%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $183m 162.34%
2025
$-118m 164.86%
unlock
2026
$-111m 6.55%
unlock
2027
$-24.6m 77.80%
unlock

Net Margin

2024 30.30% 106.26%
2025
-144.72% 577.55%
unlock
2026
-109.32% 24.46%
unlock
2027
-14.40% 86.83%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.81 -0.53
160.90% 165.43%
P/E negative

7 Analysts have issued a CureVac N.V. forecast for earnings per share. The average CureVac N.V. EPS is

$-0.53
unlock
. This is
182.81% lower
unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.14 121.88%
unlock
, the lowest is
$-0.78 221.88%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.81 160.90%
2025
$-0.53 165.43%
unlock
2026
$-0.49 7.55%
unlock
2027
$-0.11 77.55%
unlock

P/E ratio

Current 7.28 36.95%
2025
-8.86 221.68%
unlock
2026
-9.48 7.00%
unlock
2027
-42.73 350.74%
unlock

Current CureVac N.V. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
➜
Locked
Locked Jun 26 2025
Jefferies
Locked
➜
Locked
Locked Jun 13 2025
JMP Securities
Locked
➜
Locked
Locked May 28 2025
UBS
Locked
➜
Locked
Locked Apr 30 2025
JMP Securities
Locked
➜
Locked
Locked Feb 14 2025
JMP Securities
Locked
➜
Locked
Locked Sep 16 2024
Analyst Rating Date
Locked
UBS:
Locked
➜
Locked
Jun 26 2025
Locked
Jefferies:
Locked
➜
Locked
Jun 13 2025
Locked
JMP Securities:
Locked
➜
Locked
May 28 2025
Locked
UBS:
Locked
➜
Locked
Apr 30 2025
Locked
JMP Securities:
Locked
➜
Locked
Feb 14 2025
Locked
JMP Securities:
Locked
➜
Locked
Sep 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today